31 research outputs found
Hybridization and Decay of Magnetic Excitations in two-dimensional Triangular Lattice Antiferromagnets
Elementary quasiparticles in solids such as phonons and magnons occasionally
have nontrivial interactions between them, as well as among themselves. As a
result, their energy eigenvalues are renormalized, the quasiparticles
spontaneously decay into a multi-particle continuum state, or they are
hybridized with each other when their energies are close. As discussed in this
review, such anomalous features can appear dominantly in quantum magnets but
are not, a priori, negligible for magnetic systems with larger spin values and
noncollinear magnetic structures. We review the unconventional magnetic
excitations in two-dimensional triangular lattice antiferromagnets and discuss
their implications on related issues.Comment: 18 pages, 9 figure
Renormalization of spin excitations in hexagonal HoMnO3 by magnon-phonon coupling
Hexagonal HoMnO3, a two-dimensional Heisenberg antiferromagnet, has been
studied via inelastic neutron scattering. A simple Heisenberg model with a
single-ion anisotropy describes most features of the spin-wave dispersion
curves. However, there is shown to be a renormalization of the magnon energies
located at around 11 meV. Since both the magnon-magnon interaction and
magnon-phonon coupling can affect the renormalization in a noncollinear magnet,
we have accounted for both of these couplings by using a Heisenberg XXZ model
with 1=S expansions [1] and the Einstein site phonon model [13], respectively.
This quantitative analysis leads to the conclusion that the renormalization
effect primarily originates from the magnon-phonon coupling, while the
spontaneous magnon decay due to the magnon-magnon interaction is suppressed by
strong two-ion anisotropy.Comment: 5 pages, 4 figure
Spin-orbit coupling effects on spin-phonon coupling in Cd2Os2O7
Spin-orbit coupling (SOC) is essential in understanding the properties of 5d
transition metal compounds, whose SOC value is large and almost comparable to
other key parameters. Over the past few years, there have been numerous studies
on the SOC-driven effects of the electronic bands, magnetism, and spin-orbit
entanglement for those materials with a large SOC. However, it is less studied
and remains an unsolved problem in how the SOC affects the lattice dynamics.
We, therefore, measured the phonon spectra of 5d pyrochlore Cd2Os2O7 over the
full Brillouin zone to address the question by using inelastic x-ray scattering
(IXS). Our main finding is a visible mode-dependence in the phonon spectra,
measured across the metal-insulator transition at 227 K. We examined the SOC
strength dependence of the lattice dynamics and its spin-phonon (SP) coupling,
with first-principle calculations. Our experimental data taken at 100 K are in
good agreement with the theoretical results obtained with the optimized U = 2.0
eV with SOC. By scaling the SOC strength and the U value in the DFT
calculations, we demonstrate that SOC is more relevant than U to explaining the
observed mode-dependent phonon energy shifts with temperature. Furthermore, the
temperature dependence of the phonon energy can be effectively described by
scaling SOC. Our work provides clear evidence of SOC producing a non-negligible
and essential effect on the lattice dynamics of Cd2Os2O7 and its SP coupling.Comment: 12 pages, 5 figures, accepted for publication at Rapid Communication
in Physical Review
Spin texture induced by non-magnetic doping and spin dynamics in 2D triangular lattice antiferromagnet h-Y(Mn,Al)O3
Novel effects induced by nonmagnetic impurities in frustrated magnets and
quantum spin liquid represent a highly nontrivial and interesting problem. A
theoretical proposal of extended modulated spin structures induced by doping of
such magnets, distinct from the well-known skyrmions has attracted significant
interest. Here, we demonstrate that nonmagnetic impurities can produce such
extended spin structures in h-YMnO3, a triangular antiferromagnet with
noncollinear magnetic order. Using inelastic neutron scattering (INS), we
measured the full dynamical structure factor in Al-doped h-YMnO3 and confirmed
the presence of magnon damping with a clear momentum dependence. Our
theoretical calculations can reproduce the key features of the INS data,
supporting the formation of the proposed spin textures. As such, our study
provides the first experimental confirmation of the impurity-induced spin
textures. It offers new insights and understanding of the impurity effects in a
broad class of noncollinear magnetic systems.Comment: 18 pages, 4 figures and supplementary Information. Accepted for
publication in Nature Communication
Giant thermal hysteresis in Verwey transition of single domain Fe3O4 nanoparticles
Most interesting phenomena of condensed matter physics originate from
interactions among different degrees of freedom, making it a very intriguing
yet challenging question how certain ground states emerge from only a limited
number of atoms in assembly. This is especially the case for strongly
correlated electron systems with overwhelming complexity. The Verwey transition
of Fe3O4 is a classic example of this category, of which the origin is still
elusive 80 years after the first report. Here we report, for the first time,
that the Verwey transition of Fe3O4 nanoparticles exhibits size-dependent
thermal hysteresis in magnetization, 57Fe NMR, and XRD measurements. The
hysteresis width passes a maximum of 11 K when the size is 120 nm while
dropping to only 1 K for the bulk sample. This behavior is very similar to that
of magnetic coercivity and the critical sizes of the hysteresis and the
magnetic single domain are identical. We interpret it as a manifestation of
charge ordering and spin ordering correlation in a single domain. This work
paves a new way of undertaking researches in the vibrant field of strongly
correlated electron physics combined with nanoscience.Comment: 13 pages, 4 figure
Implementation of corticosteroids in treating COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK:prospective observational cohort study
BACKGROUND: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial publication on June 16, 2020, and to identify discrepancies in care. METHODS: We did an audit of clinical implementation of corticosteroids in a prospective, observational, cohort study in 237 UK acute care hospitals between March 16, 2020, and April 14, 2021, restricted to patients aged 18 years or older with proven or high likelihood of COVID-19, who received supplementary oxygen. The primary outcome was administration of dexamethasone, prednisolone, hydrocortisone, or methylprednisolone. This study is registered with ISRCTN, ISRCTN66726260. FINDINGS: Between June 17, 2020, and April 14, 2021, 47 795 (75·2%) of 63 525 of patients on supplementary oxygen received corticosteroids, higher among patients requiring critical care than in those who received ward care (11 185 [86·6%] of 12 909 vs 36 415 [72·4%] of 50 278). Patients 50 years or older were significantly less likely to receive corticosteroids than those younger than 50 years (adjusted odds ratio 0·79 [95% CI 0·70–0·89], p=0·0001, for 70–79 years; 0·52 [0·46–0·58], p80 years), independent of patient demographics and illness severity. 84 (54·2%) of 155 pregnant women received corticosteroids. Rates of corticosteroid administration increased from 27·5% in the week before June 16, 2020, to 75–80% in January, 2021. INTERPRETATION: Implementation of corticosteroids into clinical practice in the UK for patients with COVID-19 has been successful, but not universal. Patients older than 70 years, independent of illness severity, chronic neurological disease, and dementia, were less likely to receive corticosteroids than those who were younger, as were pregnant women. This could reflect appropriate clinical decision making, but the possibility of inequitable access to life-saving care should be considered. FUNDING: UK National Institute for Health Research and UK Medical Research Council
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Background:
Microbiological characterisation of co-infections and secondary infections in patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary infections, and antimicrobial use, in patients admitted to hospital with COVID-19.
Methods:
The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing, prospective cohort study recruiting inpatients from 260 hospitals in England, Scotland, and Wales, conducted by the ISARIC Coronavirus Clinical Characterisation Consortium. Patients with a confirmed or clinician-defined high likelihood of SARS-CoV-2 infection were eligible for inclusion in the ISARIC WHO CCP-UK study. For this specific study, we excluded patients with a recorded negative SARS-CoV-2 test result and those without a recorded outcome at 28 days after admission. Demographic, clinical, laboratory, therapeutic, and outcome data were collected using a prespecified case report form. Organisms considered clinically insignificant were excluded.
Findings:
We analysed data from 48 902 patients admitted to hospital between Feb 6 and June 8, 2020. The median patient age was 74 years (IQR 59–84) and 20 786 (42·6%) of 48 765 patients were female. Microbiological investigations were recorded for 8649 (17·7%) of 48 902 patients, with clinically significant COVID-19-related respiratory or bloodstream culture results recorded for 1107 patients. 762 (70·6%) of 1080 infections were secondary, occurring more than 2 days after hospital admission. Staphylococcus aureus and Haemophilus influenzae were the most common pathogens causing respiratory co-infections (diagnosed ≤2 days after admission), with Enterobacteriaceae and S aureus most common in secondary respiratory infections. Bloodstream infections were most frequently caused by Escherichia coli and S aureus. Among patients with available data, 13 390 (37·0%) of 36 145 had received antimicrobials in the community for this illness episode before hospital admission and 39 258 (85·2%) of 46 061 patients with inpatient antimicrobial data received one or more antimicrobials at some point during their admission (highest for patients in critical care). We identified frequent use of broad-spectrum agents and use of carbapenems rather than carbapenem-sparing alternatives.
Interpretation:
In patients admitted to hospital with COVID-19, microbiologically confirmed bacterial infections are rare, and more likely to be secondary infections. Gram-negative organisms and S aureus are the predominant pathogens. The frequency and nature of antimicrobial use are concerning, but tractable targets for stewardship interventions exist.
Funding:
National Institute for Health Research (NIHR), UK Medical Research Council, Wellcome Trust, UK Department for International Development, Bill & Melinda Gates Foundation, EU Platform for European Preparedness Against (Re-)emerging Epidemics, NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool, and NIHR HPRU in Respiratory Infections at Imperial College London
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Background:
Microbiological characterisation of co-infections and secondary infections in patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary infections, and antimicrobial use, in patients admitted to hospital with COVID-19.
Methods:
The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing, prospective cohort study recruiting inpatients from 260 hospitals in England, Scotland, and Wales, conducted by the ISARIC Coronavirus Clinical Characterisation Consortium. Patients with a confirmed or clinician-defined high likelihood of SARS-CoV-2 infection were eligible for inclusion in the ISARIC WHO CCP-UK study. For this specific study, we excluded patients with a recorded negative SARS-CoV-2 test result and those without a recorded outcome at 28 days after admission. Demographic, clinical, laboratory, therapeutic, and outcome data were collected using a prespecified case report form. Organisms considered clinically insignificant were excluded.
Findings:
We analysed data from 48 902 patients admitted to hospital between Feb 6 and June 8, 2020. The median patient age was 74 years (IQR 59–84) and 20 786 (42·6%) of 48 765 patients were female. Microbiological investigations were recorded for 8649 (17·7%) of 48 902 patients, with clinically significant COVID-19-related respiratory or bloodstream culture results recorded for 1107 patients. 762 (70·6%) of 1080 infections were secondary, occurring more than 2 days after hospital admission. Staphylococcus aureus and Haemophilus influenzae were the most common pathogens causing respiratory co-infections (diagnosed ≤2 days after admission), with Enterobacteriaceae and S aureus most common in secondary respiratory infections. Bloodstream infections were most frequently caused by Escherichia coli and S aureus. Among patients with available data, 13 390 (37·0%) of 36 145 had received antimicrobials in the community for this illness episode before hospital admission and 39 258 (85·2%) of 46 061 patients with inpatient antimicrobial data received one or more antimicrobials at some point during their admission (highest for patients in critical care). We identified frequent use of broad-spectrum agents and use of carbapenems rather than carbapenem-sparing alternatives.
Interpretation:
In patients admitted to hospital with COVID-19, microbiologically confirmed bacterial infections are rare, and more likely to be secondary infections. Gram-negative organisms and S aureus are the predominant pathogens. The frequency and nature of antimicrobial use are concerning, but tractable targets for stewardship interventions exist.
Funding:
National Institute for Health Research (NIHR), UK Medical Research Council, Wellcome Trust, UK Department for International Development, Bill & Melinda Gates Foundation, EU Platform for European Preparedness Against (Re-)emerging Epidemics, NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool, and NIHR HPRU in Respiratory Infections at Imperial College London
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
Background:
COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK.
Methods:
We did a prospective, multicentre cohort study in 302 UK health-care facilities. Adult patients aged 19 years or older, with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 were included in the study. The primary outcome of this study was the incidence of in-hospital complications, defined as organ-specific diagnoses occurring alone or in addition to any hallmarks of COVID-19 illness. We used multilevel logistic regression and survival models to explore associations between these outcomes and in-hospital complications, age, and pre-existing comorbidities.
Findings:
Between Jan 17 and Aug 4, 2020, 80 388 patients were included in the study. Of the patients admitted to hospital for management of COVID-19, 49·7% (36 367 of 73 197) had at least one complication. The mean age of our cohort was 71·1 years (SD 18·7), with 56·0% (41 025 of 73 197) being male and 81·0% (59 289 of 73 197) having at least one comorbidity. Males and those aged older than 60 years were most likely to have a complication (aged ≥60 years: 54·5% [16 579 of 30 416] in males and 48·2% [11 707 of 24 288] in females; aged <60 years: 48·8% [5179 of 10 609] in males and 36·6% [2814 of 7689] in females). Renal (24·3%, 17 752 of 73 197), complex respiratory (18·4%, 13 486 of 73 197), and systemic (16·3%, 11 895 of 73 197) complications were the most frequent. Cardiovascular (12·3%, 8973 of 73 197), neurological (4·3%, 3115 of 73 197), and gastrointestinal or liver (0·8%, 7901 of 73 197) complications were also reported.
Interpretation:
Complications and worse functional outcomes in patients admitted to hospital with COVID-19 are high, even in young, previously healthy individuals. Acute complications are associated with reduced ability to self-care at discharge, with neurological complications being associated with the worst functional outcomes. COVID-19 complications are likely to cause a substantial strain on health and social care in the coming years. These data will help in the design and provision of services aimed at the post-hospitalisation care of patients with COVID-19.
Funding:
National Institute for Health Research and the UK Medical Research Council